Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer )
|
|
- Bryan Miles
- 7 years ago
- Views:
Transcription
1 Departments of Haematology, Nephrology and Pharmacy Care Pathway for the Administration of Intravenous Iron Sucrose (Venofer ) [Care Pathway Review Date] Guidance for use This Care Pathway is intended as a guide to treatment and an aid to documenting patient progress. Of course practitioners are free to exercise their own professional judgement, however, any alteration to the practice identified within this care Pathway must be noted as a variance on the sheet at the back of the Pathway. (Please record alteration to practice and action taken as a result.) Name Consultant Case note number Ward Date of Admission Named Nurse Date commended on pathway Date of Discharge For information relating to the care outlined on this Pathway, please contact: Anne Waddington Pharmacy Dept Ext 3987 If you require clarification on Care Pathways in general, please contact: Clinical Governance Department Ext 6475 Iron Sucrose (Venofer) Care Pathway Page 1 of 11
2 Section 1 Assessment (to be completed by prescriber) 1. Patient Details (attach addressograph label) Name Unit number Date of Birth 2. Indications for the Use of Venofer (select indication by ticking box) Table 1. Indication Yes No 1. Does the patient have anaemia of Chronic Kidney disease with ferritin <200 mcg/l or total iron saturation (TSAT) <20%? 2. Is the patient intolerant or resistant to oral iron therapy? 3. Is oral iron therapy unsuitable or contraindicated? Other indication:.. Signature of prescriber Iron Sucrose (Venofer) Care Pathway Page 2 of 11
3 3. Cautions and Contraindications to the use of Venofer (to be completed by the prescriber) Venofer must not be given if the patient has any of the following contraindications. Please complete the table below stating yes or no as appropriate. Table 2 Contraindications to Venofer Yes No Non iron deficient anaemia (e.g. haemolytic anaemia) Iron overload or disturbance of iron utilisation History of asthma, eczema or atopic allergy Drug hypersensitivity to parenteral iron preparations Decompensated liver cirrhosis or hepatitis Acute/chronic infection of any type Pregnancy first trimester Occasionally iron infusion may be given with steroid cover for patients who have shown a mild reaction to the infusion in the past. This should be requested by the referring consultant. Cautions Parenterally administered iron preparations can cause allergic or anaphylactoid reactions, which may be potentially fatal. Therefore, treatment for serious allergic reactions and facilities with the established cardiopulmonary resuscitation procedures should be available. In patients with liver dysfunction, parenteral iron should only be administered after careful risk/benefit assessment. Parenteral iron administration should be avoided in patients with hepatic dysfunction where iron overload is a precipitating factor, in particular Porphyria Cutanea Tarda (PCT). Careful monitoring of iron status is recommended to avoid iron overload. Parenteral iron must be used with caution in case of acute or chronic infection. It is recommended that the administration of iron sucrose is stopped in patients with ongoing bacteraemia. In patients with chronic infection a risk/benefit evaluation has to be performed, taking into account the suppression of erythropoiesis. Hypotensive episodes may occur if the injection is administered too rapidly. Allergic reactions, sometimes involving arthralgia, have been more commonly observed when the recommended dose is exceeded. Paravenous leakage must be avoided because leakage of Venofer at the injection site may lead to pain, inflammation, tissue necrosis and brown discoloration of the skin Iron Sucrose (Venofer) Care Pathway Page 3 of 11
4 Contraindications discussed with referring consultant Yes No Date Name of consultant Time Signature Outcome: To be completed by prescriber 4. Dose of Intravenous Iron Please tick Yes No Does the patient have anaemia of Chronic Kidney disease with ferritin <200 mcg/l or total iron saturation (TSAT) <20% but is not dialysis dependent? If yes, use table 3 (on page 5) to calculate dose of Venofer. Is the patient dialysis dependent with ferritin <200 mcg/l or total iron saturation (TSAT) <20%? If yes use table 4 (on page 5) to calculate dose of Venofer Is patient iron deficient with Haemoglobin < 11 g/dl and either a) intolerant or resistant to oral iron therapy or b) oral iron therapy is unsuitable or contraindicated? If yes, see table 5 (on page 6) for dose of Venofer. For other indications consult product literature and discuss dosage with pharmacy. Please tick Yes No Dosage discussed with pharmacy Name of Pharmacist Date: Time: Signature: Iron Sucrose (Venofer) Care Pathway Page 4 of 11
5 Venofer may be administered up to maximum of 200mg three times weekly. If a less rapid correction is required Venofer may be given as 200mg weekly for the required number of doses. Table 3 Total Number of doses of Venofer for non dialysis patients with anaemia of Chronic Kidney Disease Patient Weight Number of doses of Venofer (kg) mg up to a maximum of three times weekly for 3 doses mg up to a maximum of three times weekly for 4 doses >50 200mg up to a maximum of three times weekly for 5 doses Consider prescribing a maintenance regime for replacement of iron in patients with anaemia of chronic kidney disease, particularly if they are receiving an Erythropoeisis Stimulating Agent e.g. Aranesp. Table 4 Total Number of doses of Venofer for haemodialysis patients with anaemia of Chronic Kidney Disease Patient Weight Dose of Venofer Haemodialysis patients (kg) Induction Maintenance dose mg three times weekly for 3 doses 100mg monthly mg three times weekly for 4 doses 100mg fortnightly >50 200mg three times weekly for 5 doses 100mg weekly Dialysis patients often require intravenous iron supplementation to be continued after the initial replacement dose. The maintenance dose schedule in Table 4 above may be used and modified as appropriate based on patient s Haematinics. Iron Sucrose (Venofer) Care Pathway Page 5 of 11
6 Table 5 Total Dose of Venofer for patients with haemoglobin < 11 g/dl who do not have anaemia of chronic kidney disease and in whom oral iron is unsuitable. How to use table 5 to select the correct dose of Venofer In the left hand column, find the body weight that most closely matches the patient s bodyweight. Read across this row to the column headed by the haemoglobin concentration that matches the patient s current state. The reading at this point gives the total dose Venofer that the patient should receive to correct their iron stores. Divide the total dose by 200 to give the number of doses of 200mg of Venofer that the patient requires to complete their treatment. For example an 80kg patient with a haemoglobin of 7g/dL would require 1200mg of Venofer. This could be given as a 2 week course of 200mg three times per week. Haemoglobin Concentration g/dl) Body Weight (Kg) g/dl 6 g/dl 7 g/dl 8 g/dl 9 g/dl 10 g/dl NB This is the total dose of Venofer needed. It is not the dose to be given in one treatment. The maximum dose of Venofer that can be given in one week is 200mg three times weekly. Iron Sucrose (Venofer) Care Pathway Page 6 of 11
7 To be completed by prescriber 5. Prescription of Venofer Venofer should be prescribed on the patient s drug Kardex or outpatient prescription. The required dose of Venofer is given in 100 ml Sodium Chloride 0.9%. Give the first 25mg of the infusion as a test dose over 15 minutes. If no adverse reactions the remainder of the infusion should be given over 30 minutes. Venofer may also be given undiluted into the venous limb of the dialyser. In this case the first 1mL (20mg) of Venofer should be given as a test dose over 1 to 2 minutes. If there is no reaction in the 15 minutes after the test dose the remaining portion of the dose may be given over 5 minutes. 6. Monitoring 6.1 Haematinics. Record patients blood results pre-treatment. Ensure patient is given 2 blood test forms when they receive Venofer infusion so that their haematinics can be rechecked as an Outpatient at week 4 and week 12. Correct B 12 and folate as appropriate. Ferritin Normal Ferritin range is mcg/l. For anaemia management in Chronic Kidney disease aim for ferritin mcg/l. Iron infusion must not be given if Ferritin>800 mcg/l unless discussed with referring consultant. Date Hb B Week 0 (baseline) nanogram/l Serum Folate mcg/l Ferritin Iron µmol/l Iron Saturation % Week 4 Week 12 Repeat test not Required if normal at baseline Iron Sucrose (Venofer) Care Pathway Page 7 of 11
8 7. Administration (To be completed by person administering the Venofer ) Add the prescribed amount of Venofer to 100mL of sterile normal sodium chloride using aseptic technique. Prescribed amount of Venofer added to 100ml of sterile normal sodium chloride using aseptic technique. 8. Observations during Venofer Infusion Anaphylactoid reactions Yes No Signature and Print Name Anaphylactoid reactions to Venofer are usually evident within a few minutes, and close observation is necessary to ensure recognition. If no adverse reactions are seen after 15 minutes, give the remaining portion of the infusion over at least 30 minutes. Observe patient every 5 minutes whilst the test dose is being given and then every 15 minutes until infusion is completed. Complete the observations chart below (on page 9), recording Heart Rate, Blood Pressure, Respiratory Rate and Temperature. If at any time during the intravenous administration of Venofer, any signs of a hypersensitivity reaction or intolerance are detected, administration must be stopped immediately. Facilities for cardio-pulmonary resuscitation including adrenaline (1:1000) must be available when administering Venofer Iron Sucrose (Venofer) Care Pathway Page 8 of 11
9 Record of Venofer Administration (To be completed by person administering Venofer ) Attach Cannulation Sticker here Verbal consent for treatment given Venofer Batch Number: Venofer Expiry Date./ % Saline Batch Number. 0.9% Saline Expiry Date./ Yes No Test dose started Signature Test dose stopped Signature Time Time Observations Chart to be used During Venofer Infusion Date Time Heart Rate Blood Pressure Respiratory Rate Temperature Free from side effects Yes *No * If no, record in variance section and follow Section 9 management of side effects of intravenous iron Iron Sucrose (Venofer) Care Pathway Page 9 of 11
10 To be completed by attending medic 9. Management of Side Effects of Intravenous Iron Side Effect Action Required Action Taken Date / Time Anaphylaxis Stop infusion. Yes No Signature Give Hydrocortisone 100mg iv. Give Chlorphenamine 10mg iv. Consider also giving 1mg of Intramuscular adrenaline (1:1000) if the patient shows signs of cardiovascular compromise. Mild allergic reaction Hypotension * May be as a result of administering intravenous iron too quickly. Injection Site Pain * Extravasation Record Anaphylactic reaction in case notes and do not use intravenous iron again in this patient. Stop intravenous infusion. Administer Chlorphenamine 10mg iv. Stop infusion. Lay patient flat. Recommence infusion at half of previous rate when systolic BP has recovered to >100mmHg. Stop infusion. Confirm venflon is sited correctly. Emergency Drugs Hydrocortisone 100mg i.v. Time: Signature: Chlorphenamine 10mg i.v. Time: Signature: Adrenaline (1:1000) 1mg i.m. Time: Signature Iron Sucrose (Venofer) Care Pathway Page 10 of 11
11 Venofer Variance Sheet All Staff Patient ID Label Reference Variance Iron Sucrose (Venofer) Care Pathway Page 11 of 11
Beaumont Hospital Department of Nephrology and Renal Nursing. Guideline for administering Ferinject
Beaumont Hospital Department of Nephrology and Renal Nursing Guideline Name: Guideline for administering Ferinject Guideline Number: 18 Guideline Version: a Developed By: Louise Kelly CNM 1 Renal Day Care
More informationBEAUMONT HOSPITAL DEPARTMENT OF NEPHROLOGY RENAL BIOPSY
1 BEAUMONT HOSPITAL DEPARTMENT OF NEPHROLOGY GUIDELINES ON ADMINISTRATION OF INTRAVENOUS IRON SUCROSE (VENOFER) AS A BOLUS DOSE IN THE RENAL OUTPATIENT SETTING Date Developed: August- October 2007 RENAL
More informationGloucestershire Hospitals
Gloucestershire Hospitals NHS Foundation Trust TRUST GUIDELINE INFLIXIMAB PRESCRIBING AND ADMINISTRATION 1. INTRODUCTION Infliximab is an anti-tumour necrosis factor-α (Anti-TNF) antibody. It is from a
More informationDATA SHEET VENOFER. Pharmacotherapeutic group: Anti-anaemic preparation, iron, parenteral preparation, ATC code: B03AC.
DATA SHEET VENOFER Iron Sucrose PRESENTATION Venofer is a dark brown, non transparent, sterile aqueous solution of iron sucrose in water for injections with a ph of 10.5-11.0 and an osmolarity of 1,150-1,350
More informationYes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
Title: Patient Group Direction for the administration of lidocaine hydrochloride 1% injection as infiltration anaesthesia for insertion/removal of central venous catheters by nurses/radiographers working
More informationRecommended guidelines for. schools
Recommended guidelines for medication administration in schools Objective At the end of the session the nurses will be aware of the HAAD standards and roles and responsibilities of a nurse in medication
More informationPOAC CLINICAL GUIDELINE
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
More informationONCE ONLY GLUCAGON and Fast Acting Glucose gel (PGD) For nurse administration under Patient Group Direction (Trust wide PGD in place)
ADULT INSULIN PRERIPTION AND BLOOD GLUCOSE MONITORING CHART Ward CONSULTANT DATE OF ADMISSION Please affix Patient s label here Ward Ward.../...year PATIENT NAME....... DATE OF BIRTH... NHS NUMBER.......
More informationPackage leaflet : information for the user. Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.
Package leaflet : information for the user Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.1mg per ml Because of your condition it may not be possible for
More informationReview Group: Mental Health Operational Medicines Management Group. Signature Signature Signature. Review Date: December 2014
Mental Health NHS Grampian Mental Health Service Staff Guidance For The Prescribing Of Vitamin Supplementation During In-Patient Admission (Mental Health) For Alcohol Withdrawal Co-ordinators: Consultant
More informationGUIDELINE FOR ADMINISTRATION OF FENTANYL FOR PAIN RELIEF IN LABOUR
GUIDELINE FOR ADMINISTRATION OF FENTANYL FOR PAIN RELIEF IN LABOUR INTRODUCTION Intravenous (IV) Fentanyl is a good option for pain management during labour and should be administered in a safe and competent
More informationAdministration of Medications & Fluids via a Peripheral Intravenous Cannula
Administration of Medications & Fluids via a Peripheral Intravenous Cannula Clinical S.O.P. No.: 22.0 Compiled by: Approved by: Review date: November 2016 Administration of Medications & Fluids via S.O.P.
More informationAll Wales Prescription Writing Standards
All Wales Prescription Writing Standards These standards should be read in conjunction with completing the All Wales Medication Chart e- learning package, available on the Learning@NHSWales internet site
More informationAdministering blood transfusion
Administering blood transfusion 1 Cherry Buckwell, CETL Interprofessional Clinical Skills Facilitator Is it safe? Approximately 3.34 million blood products are transfused each year in the UK. Blood transfusions
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully before you start using this
More informationProtocol for the safe administration of iodinated contrast media in diagnostic radiology
Protocol for the safe administration of iodinated contrast media in diagnostic radiology Protocol statement: This protocol applies to all staff within Radiology Departments at Heart of England NHS Foundation
More informationI B2.4. Design of the patient information leaflet for VariQuin
(English translation of official Dutch version) I B2.4. Design of the patient information leaflet for VariQuin Information for the Patient: Read this package leaflet carefully when you have some time to
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin
PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because
More information8.5 Geriatric Use * Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Injectafer safely and effectively. See full prescribing information for Injectafer. INJECTAFER (ferric
More information3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP
PRESCRIBING INFORMATION 3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP IV Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of Revision:
More informationLung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)
Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed
More informationHealth Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 2 Hospital Pharmacy Standards of Practice Table of Contents 1. Application 2. Definitions 3. Drug Distribution 4. Drug Label 5. Returned Drugs 6. Drug Transfer
More informationLaboratory Monitoring of Adult Hospital Patients Receiving Parenteral Nutrition
Laboratory Monitoring of Adult Hospital Patients Receiving Parenteral Nutrition Copy 1 Location of copies Web based only The following guideline is for use by medical staff caring for the patient and members
More informationNHSG/PGD/lido_eton/MGPG412 Organisation Wide
Title: Patient Group Direction For The Administration Of Lidocaine 2% Injection For The Insertion/Removal Of The 68mg Etonogestrel Contraceptive Implant By Nurses And Midwives Working Within NHS Grampian
More informationtrust clinical guideline
CG04 VERSION 1.0 1/5 Guideline ID CG04 Version 1.0 Title Approved by Allergic Reactions Clinical Effectiveness Group Date Issued 01/01/2013 Review Date 31/12/2016 Directorate Authorised Staff Clinical
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion. Paracetamol
PACKAGE LEAFLET: INFORMATION FOR THE USER PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion Paracetamol Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationSTANDARD OPERATING PROCEDURE. Administration of High Dose Muscular Vitamin Supplements for Undergoing Alcohol
STANDARD OPERATING PROCEDURE Administration of High Dose Muscular Vitamin Supplements for Undergoing Alcohol DOCUMENT CONTROL: Version: 2 Ratified by: Clinical Effectiveness Committee Date ratified: 03
More informationPHENYLEPHRINE HYDROCHLORIDE INJECTION USP
PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada
More informationVersion 2 This guideline describes how to manage patients who are showing signs and symptoms of alcohol withdrawal and Wernicke s Encephalopathy.
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality A Guideline for the Management of Acute Alcohol Withdrawal
More informationpatient group direction
DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationMedicines Management
Medicines Management Patient Group Direction for the Supply/administration of Adrenaline (Epinephrine) for Treatment of Anaphylaxis by accredited community Pharmacists. Rationale To enable a pharmacist,
More informationMedicines reconciliation on admission and discharge from hospital policy April 2013. WHSCT medicines reconciliation policy 1
Medicines reconciliation on admission and discharge from hospital policy April 2013 WHSCT medicines reconciliation policy 1 Policy Title Policy Reference Number Medicines reconciliation on admission and
More informationDeveloped / Reviewed by the Collaborative Provider PGD (Patient Group Direction) Group (CPPGDG) and approved by the following members of the CPPGDG:
Patient Group Direction 7.02 version 4.0 Administration of Intravenous Adrenaline (Epinephrine) 1 in 10,000 (100micrograms per ml) Injection in Cardiopulmonary by Registered Practitioners in Torbay and
More informationUW School of Dentistry Comprehensive Medication Policy
UNIVERSITY OF WASHINGTON SCHOOL OF DENTISTRY Subject: UW School of Dentistry Comprehensive Medication Policy Policy Number: Effective Date: December 2014 Revision Dates: June 2015 PURPOSE This policy provides
More informationLOW T NATION TESTOSTERONE INTAKE FORM NAME: DATE: ADDRESS: CITY: STATE: ZIP: CELL #: HOME #: SOC SECURITY #: DATE OF BIRTH:
LOW T NATION TESTOSTERONE INTAKE FORM NAME: DATE: ADDRESS: CITY: STATE: ZIP: CELL #: HOME #: SOC SECURITY #: DATE OF BIRTH: DRIVERS LICENSE NUMBER: STATE: EMAIL ADDRESS: MARITAL STATUS: ( ) SINGLE ( )
More informationThe Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
More informationANAPHYLAXIS. Introduction. Differential Diagnosis. Starship Children s Health Clinical Guideline
Introduction Differential Diagnosis Management Treatment of Anaphylaxis (Flow Chart) Disposition from Emergency Department Adrenaline Autoinjectors Action Plan Adrenaline Autoinjector Information Sheet
More informationClinical Performance Director of Nursing Allison Bussey
PGD 0314 Patient Group Direction Administration of Adrenaline (Epinephrine) 1:1000 (1mg/ml) Injection By Registered Nurses employed by South Staffordshire & Shropshire Healthcare Foundation NHS Trust This
More informationProvision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine
Provision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine Guideline Updated: August 2010 Replaced: November 1998 To serve the public and guide the medical profession EDTA Chelation
More informationFURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES
FURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES Dr Alison Jones Great Ormond Street Hospital for Children NHS Trust London WC1N 3JH United Kingdom
More informationEmergency Treatment of an Anaphylactic Reaction in the Community Protocol
Emergency Treatment of an Anaphylactic Reaction in the Community Protocol Reference Number: NHSCT/09/216 Responsible Directorate: Children s Services Replaces (if appropriate): Northern Trust Departmental
More informationThe reaction is termed anaphylaxis if there are life-threatening features such as respiratory difficulties and/or hypotension.
HYPERSENSITIVITY AND ANAPHYLACTIC REACTIONS DURING AND AFTER TREATMENT WITH CHEMOTHERAPY- CLINICAL GUIDELINE FOR RECOGNITION AND TREATMENT. 1. Aim/Purpose of this Guideline 1.1. The aim of this document
More informationEmergency Treatment of Anaphylaxis Policy and Guidelines
Emergency Treatment of Anaphylaxis Policy and Guidelines This procedural document supersedes: PAT/EC 3 v.4 Policy and Guidelines for the Emergency Treatment of Anaphylaxis This procedural document should
More informationCyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft
INDICATIONS Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft Aplastic Anaemia (patients under 40 years) PRE-ASSESSMENT Ensure pre-transplant work-up form is complete Ensure patient has triple
More informationGuidelines for anaphylaxis emergency medication (adrenaline [epinephrine] autoinjector) prescription
Guidelines for anaphylaxis emergency medication (adrenaline [epinephrine] autoinjector) prescription Introduction The aim of these guidelines is to outline the appropriate prescription of adrenaline (epinephrine)
More informationANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Isoproterenol Major Indications Status Asthmaticus As a last resort for
More informationInitiate Atorvastatin 20mg daily
Type 2 Diabetes Patient Objectives Stopping Smoking BMI > 25 kg m² Control BP to
More informationCytotoxic and Biotherapies Credentialing Programme Module 5
Cytotoxic and Biotherapies Credentialing Programme Module 5 1. Drug Dose Determination 2. Drug Calculations 3. Role of the Second Checker 4. The Checking Process At the completion of this module the RN
More informationHumulin R (U500) insulin: Prescribing Guidance
Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring
More informationEmergency Anaphylaxis Management: Opportunities for Improvement. Ronna Campbell, MD, PhD August 31, 2015
Emergency Anaphylaxis Management: Opportunities for Improvement Ronna Campbell, MD, PhD August 31, 2015 disclosures Anaphylaxis Roundtable discussion held at the 2014 American College of Allergy, Asthma
More informationIntravenous Therapy Principles of Care. Breege Smithers Practice Educator
Intravenous Therapy Principles of Care Breege Smithers Practice Educator Objectives State indications for intravenous therapy List the advantages and disadvantages of intravenous therapy Identify the principles
More informationCLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS 1. Aim/Purpose of this Guideline 1.1. Systemic cancer treatments and immunological therapies can suppress the ability of the bone
More informationMEDICAL DIRECTIVES POLICY
MEDICAL DIRECTIVES POLICY Registered Nurses (RN=s), Nurse Practitioners (RNEC) Registered Practical Nurses (RPN) and Medical Doctors work collaboratively to provide high quality health care to the clients/patients
More informationMedications or therapeutic solutions may be injected directly into the bloodstream
Intravenous Therapy Medications or therapeutic solutions may be injected directly into the bloodstream for immediate circulation and use by the body. State practice acts designate which health care professionals
More informationRegimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral)
Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral) Indication CLL 1st line as per NICE TAG 174 CLL (relapsed) as per NICE TAG 193 Regimen details Day Drug Dose Route Cycle 1 1 Rituximab 375mg/m
More informationBilling and Coding Guide
Billing and Coding Guide INDICATIONS Injectafer is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to or have had unsatisfactory
More information3 Regime Prescription Practical considerations 4 Pre-infusion Assessment 4 Administration. 5 Checklist. 5 Administering the infusion
Guidelines for the use and administration of Rituximab in Rheumatoid Arthritis (RA) (To be used in conjunction with local policies for intravenous infusions) Contents Page Introduction 1 Licensed Indication
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (HCl) STEROP 0,8mg/1ml. Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (HCl) STEROP 0,4mg/1ml ADRENALINE (HCl) STEROP 0,8mg/1ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully
More informationManagement of an anaphylactic reaction to Omalizumab (Xolair) drug therapy
Management of an anaphylactic reaction to Omalizumab (Xolair) drug therapy Turnberg Building Respiratory Medicine 0161 206 3158 All Rights Reserved 2014. Document for issue as handout. What is an allergic
More informationPG Certificate / PG Diploma / MSc in Clinical Pharmacy
PG Certificate / PG Diploma / MSc in Clinical Pharmacy Programme Information September 2014 Entry School of Pharmacy Queen s University Belfast Queen s University Belfast - Clinical Pharmacy programme
More informationDISCHARGE CRITERIA FOR PHASE I & II- POST ANESTHESIA CARE
REFERENCES: The Joint Commission Accreditation Manual for Hospitals American Society of Post Anesthesia Nurses: Standards of Post Anesthesia Nursing Practice (1991, 2002). RELATED DOCUMENTS: SHC Administrative
More informationSummary of EWS Policy for NHSP Staff
Summary of EWS Policy for NHSP Staff For full version see CMFT Intranet Contact Sister Donna Egan outreach coordinator bleep 8742 Tel: 0161 276 8742 Introduction The close monitoring of patients physiological
More informationNHS FORTH VALLEY Adult Adrenal Insufficiency Management Guidelines
NHS FORTH VALLEY Adult Adrenal Insufficiency Management Guidelines Date of First Issue 01 August 2006 Approved 01 August 2006 Current Issue Date 30 th May 2014 Review Date 1 st July 2018 Version 1.2 EQIA
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
More informationMODERATE SEDATION RECORD (formerly termed Conscious Sedation)
(POLICY #DOC-051) Page 1 of 6 WELLSPAN HEALTH - YORK HOSPITAL NURSING POLICY AND PROCEDURE Dates: Original Issue: September 1998 Annual Review: March 2012 Revised: March 2010 Submitted by: Brenda Artz
More informationVIVITROL (EXTENDED-RELEASE INJECTABLE NALTREXONE) MEDICAL PROTOCOL AND PROCEDURES
VIVITROL (EXTENDED-RELEASE INJECTABLE NALTREXONE) MEDICAL PROTOCOL AND PROCEDURES INTRODUCTION This is the protocol and procedures to administer VIVITROL (extended-release naltrexone injection, or XR-NTX)
More information1.4.4 Oxyhemoglobin desaturation
Critical Care Therapy and Respiratory Care Section Category: Clinical Section: Clinical Monitoring Title: Monitoring of Patients Undergoing Conscious Sedation Policy #: 09 Revised: 05/00 1.0 DESCRIPTION
More informationIntraosseous Vascular Access and Lidocaine
Intraosseous Vascular Access and Lidocaine Intraosseous (IO) needles provide access to the medullary cavity of a bone. It is a technique primarily used in emergency situations to administer fluid and medication
More informationStowe School Medications Policy
INTRODUCTION Most pupils will need medication at some stage of their school life. Although this will mainly be for short periods there are a few pupils with chronic conditions who may require regular medication
More informationALBERTA IMMUNIZATION POLICY GUIDELINES
ALBERTA IMMUNIZATION POLICY GUIDELINES Hepatitis Vaccines. Hepatitis A Vaccines Refer to the vaccine product monograph and the Canadian Immunization Guide for further Product monographs are available on
More informationEmergency treatment of anaphylactic reactions
Emergency treatment of anaphylactic reactions Emergency treatment of anaphylactic reactions Objectives - to understand: What is anaphylaxis? Who gets anaphylaxis? What causes anaphylaxis? How to recognise
More informationSOP for Screening of Adult Chemotherapy Electronic Prescriptions
SOP for Screening of Adult Chemotherapy Electronic Prescriptions Contents The following steps should be followed in screening a chemotherapy prescription on ARIA: 1. Patient details 2 2. Patient medical
More informationStandards of Practice for Pharmacists and Pharmacy Technicians
Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the law
More informationJeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins)
Jeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins) I HEAR YA KNOCKING BUT YOU CAN T COME IN (electrolytes) TAKE MY BREATH AWAY (Opiates-morphine) OUT WITH
More informationCH CONSCIOUS SEDATION
Summary: CH CONSCIOUS SEDATION It is the policy of Carondelet Health that moderate conscious sedation of patients will be undertaken with appropriate evaluation and monitoring. Effective Date: 9/4/04 Revision
More informationGilenya. Exceptional healthcare, personally delivered
Gilenya Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Gilenya. The decision to start this form of treatment can be difficult.
More informationRise of the killer peanuts
Rise of the killer peanuts Epi Then, Epi Now Taher Vohra, MD Henry Ford Hospital Department of Emergency Medicine ObjecCves To define anaphylaxis To review the epidemiology of anaphylaxis To discuss treatments
More informationEpidural Management. Policy/Purpose. Scope
Fluid & Medications Management Policy/Purpose... 1 Scope... 1 Associated documents... 2 General... 2 Epidural Indications... 2 Contra-indications:... 2 Educational requirements... 3 Procedural Considerations...
More informationGUIDELINES FOR THE USE OF PALIPERIDONE PALMITATE (Xeplion ) Version: 2
SH CP 29 GUIDELINES FOR THE USE OF PALIPERIDONE PALMITATE (Xeplion ) Summary: Guidelines for the use of paliperidone palmitate (Xeplion ) Keywords (minimum of 5): (To assist policy search engine) Target
More informationINFUSE Bone Graft. Patient Information Brochure
INFUSE Bone Graft Patient Information Brochure This Patient Guide is designed to help you decide whether or not to have surgery using INFUSE Bone Graft to treat your broken tibia (lower leg). There are
More informationPatient Sticker Multiple Sclerosis Ambulatory Emergency Care Pathway
Multiple Sclerosis Ambulatory Emergency Care Pathway 1 Consultant: Dr M Oldfield Consultant: Dr D Harris Lead Nurse: Catie Paterson Ambulatory Emergency Care (AEC) Unit Patient From ED (Emergency Department)
More informationHypoglycemia (Technician-Paramedic) Protocol revised October 2008
Hypoglycemia (Technician-Paramedic) Protocol revised October 2008 Preamble Prolonged hypoglycemia may result in serious neurologic complications and death. Glucose and glucagon can be administered to correct
More informationLEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationVENOFER PRODUCT MONOGRAPH. Iron Sucrose injection, USP. 5 ml Single Dose Vials, 20 mg elemental iron/ml. Hematinic
PRODUCT MONOGRAPH VENOFER Iron Sucrose injection, USP 5 ml Single Dose Vials, 2 mg elemental iron/ml Hematinic Manufactured by: Luitpold Pharmaceuticals, Inc. One Luitpold Drive, P.O. Box 91 Shirley, New
More informationSeven steps to patient safety The full reference guide. Second print August 2004
Seven steps to patient safety The full reference guide Second print August 2004 National Patient Safety Agency Seven steps to patient safety 113 Appendix Four F Examples of events according to severity
More informationDNH 120 Management of Emergencies
Revised: Fall 2015 DNH 120 Management of Emergencies COURSE OUTLINE Prerequisites: None Course Description: Studies the various medical emergencies and techniques for managing emergencies in the dental
More informationEmergency Treatment of Anaphylactic Reactions
Emergency Treatment of Anaphylactic Reactions Authorising Officer Signature Of Authorising Officer: Tom Cahill, Deputy Chief Executive Version: V3 Ratified By: HPFT Drugs and Therapeutic Committee Date
More informationInfluenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1)
Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) This Influenza Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses (
More informationCICLOSPORIN. What are the aims of this leaflet?
CICLOSPORIN What are the aims of this leaflet? This leaflet has been written to help you understand more about ciclosporin. It tells you what it is, how it works, how it is used to treat skin conditions,
More informationAdrenaline autoinjector (EpiPen) for acute allergic anaphylaxis
for acute allergic anaphylaxis This review of adrenaline autoinjector was first published in December 2003. This update describes the change to the PBS listing to allow prescribing immediately after hospital
More information0.9% Sodium Chloride Injection, USP In VIAFLEX Plastic Container
Page 1 of 8 PRESCRIBING INFORMATION 0.9% Sodium Chloride Injection, USP In VIAFLEX Plastic Container IV Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of
More informationINFeD (IRON DEXTRAN INJECTION USP) Rx only Revised: January 2014 255769
INFeD (IRON DEXTRAN INJECTION USP) Rx only Revised: January 2014 255769 BOXED WARNING WARNING: RISK FOR ANAPHYLACTIC-TYPE REACTIONS Anaphylactic-type reactions, including fatalities, have followed the
More informationNational Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS Below is a template that can be used to produce a local patient group direction (PGD) for the administration of
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
More informationEpinephrine Administration Training for Unlicensed School Personnel
Epinephrine Administration Training for Unlicensed School Personnel Management of Life-Threatening Allergies in the School Setting Dover and Sherborn Schools EpiPen Administration This program is designed
More informationAdult Chemotherapy Induced Anaphylaxis Policy
Adult Chemotherapy Induced Anaphylaxis Policy The Beatson West of Scotland Cancer Centre 1053 Great Western Road Glasgow G12 0YN Written by: Elaine Barr Authorised by: D.Dunlop, C. Forte Issue Number :
More informationMEDICATION MANUAL Policy & Procedure
MEDICATION MANUAL Policy & Procedure TITLE: Section: Initial Management of Anaphylaxis Following Immunization Medication Specific NUMBER: MM 20-005 Date Issued: October 2009 Source: Distribution: Capital
More informationMEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate
MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate Read this Medication Guide before you start receiving mitoxantrone and each time you receive mitoxantrone. There may be new information.
More informationGESTATIONAL DIABETES (DIET/INSULIN/METFORMIN) CARE OF WOMEN IN BIRTHING SUITE
GESTATIONAL DIABETES (DIET/INSULIN/METFORMIN) CARE OF WOMEN IN BIRTHING SUITE DEFINITION A disorder characterised by hyperglycaemia first recognised during pregnancy due to increased insulin resistance
More information